NL-OMON46304已完成2 期
A Phase 2a Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Parallel Group, Dose-Range Finding Study of MVT-602 in Healthy Premenopausal Women Undergoing Controlled Ovarian Stimulation (COS) Using a Minimal Stimulation Protocol. - 180145 MVT-602-009
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 85
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Premenopausal female between 18 and 35 years of age inclusive, at the time of the screening visit.
排除标准
- •Clinical significant abnormalities at medical research;Subject has a history of menstrual cycle length that is typically shorter than 21 days or longer than 35 days when not using hormonal contraception.;Subject has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV), human immunodeficiency virus (HIV) antibody, determined from the screening visit.
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the sex-hormone-stimulant study drug MVT-602 in healthy fertile women.EUCTR2018-001379-20-NLMyovant Sciences GmbH85
已完成
不适用
A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Patients With Type 2 Diabetes MellitusPER-013-10Astellas Pharma Global Development, Inc. (APGD),
已完成
2 期
A study to evaluate the effect of ASP 1941 in adult patients with type 2 diabetes mellitusCTRI/2010/091/000343Astellas Pharma Inc378
招募中
2 期
A clinical trial to study the side effects of a drug, MBX-2982 and also to study how well it works and is tolerated when compared to a placebo and a comparator in patients with Type 2 Diabetes Mellitus.CTRI/2010/091/000162Metabolex Inc100
进行中（未招募）
不适用
A Phase IIa, Randomized, Double-Blind, Placebo- and Active- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Womevasomotor symptoms (hot flashes)MedDRA version: 12.1Level: LLTClassification code 10060800Term: Hot flushEUCTR2009-016070-33-DKMerck Sharp & Dohme Corp.300